Scancell has made meaningful progress on many fronts during the first six months of2019, ahead of clinical trials starting in the coming year. The Phase II trial with ImmunoBody SCIB1 in combination with pembrolizumab will start recruiting patients in the UK in the coming weeks. Regulatory and ethical approval was received in April, and clinical centre initiation has since been completed. In the US, Scancell is working with Ichor to address the FDA’s specific questions regarding the TriGrid v2.0 electroporation delivery device for SCIB1, currently the companies are awaiting feedback from the FDA on the IND, which is needed for the US arm of the trial to be initiated.
01 Jul 2019
Ground prepared for an important period 1 July 2019
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Ground prepared for an important period 1 July 2019
Scancell Holdings Plc (SCLP:LON) | 9.6 0 0.0% | Mkt Cap: 88.6m
- Published:
01 Jul 2019 -
Author:
Mick Cooper PhD -
Pages:
2
Scancell has made meaningful progress on many fronts during the first six months of2019, ahead of clinical trials starting in the coming year. The Phase II trial with ImmunoBody SCIB1 in combination with pembrolizumab will start recruiting patients in the UK in the coming weeks. Regulatory and ethical approval was received in April, and clinical centre initiation has since been completed. In the US, Scancell is working with Ichor to address the FDA’s specific questions regarding the TriGrid v2.0 electroporation delivery device for SCIB1, currently the companies are awaiting feedback from the FDA on the IND, which is needed for the US arm of the trial to be initiated.